AG真人官方

USANA Health Sciences (USNA) filed a Form 144 indicating an insider鈥檚 intent to sell 3,515 common shares through Morgan Stanley Smith Barney on or after 30 Jul 2025. The shares have an aggregate market value of $106,364, based on the filing date, and represent roughly 0.02 % of the company鈥檚 18.6 million shares outstanding.

The stock being sold was acquired as restricted-stock awards: 1,138 shares granted on 4 Feb 2022 and 2,377 shares granted on 6 Feb 2025. No prior insider sales were reported in the past three months, and the filer affirms possession of no undisclosed material adverse information.

The transaction is modest relative to USNA鈥檚 float and appears to be a routine liquidity event rather than a signal of fundamental change. Nevertheless, investors often monitor Form 144 filings for potential sentiment shifts among insiders.

The Vanguard Group filed Amendment 20 to Schedule 13G reporting its passive ownership in Welltower Inc. (WELL) as of 30 June 2025.

• Shares owned: 85,785,659
• Ownership percentage: 13.11 % of outstanding common stock
• Voting power: Sole 鈥� 0; Shared 鈥� 1,185,096
• Dispositive power: Sole 鈥� 82,347,104; Shared 鈥� 3,438,555
• Filer classification: Investment Adviser (Rule 13d-1(b)(1)(ii)(E))

The filing confirms that Vanguard鈥檚 stake is held in the ordinary course of business with no intent to influence control. Although Vanguard controls more than 5 %, its lack of sole voting power underscores a purely passive position. The update solidifies strong institutional ownership of WELL, but does not signal strategic changes or governance activism.

USNA 鈥� Form 4 (filed 28 Jul 2025) discloses that Chief Scientific Officer Kathryn M. Armstrong exercised 1,165 restricted stock units (RSUs) on 25 Jul 2025 (code M). Each RSU converted into one common share.

To satisfy tax-withholding obligations, the issuer automatically withheld 517 shares at $31.95 per share (code F). As a result, Armstrong鈥檚 net direct ownership increased by 648 shares, ending at 648 common shares. The derivative table shows 20,256 unvested/remaining RSUs still held after the transaction. The reported RSUs vest 25 % annually from the original 25 Jul 2024 grant date.

No open-market purchases or sales were executed; activity relates solely to equity award settlement. Impact on the float and insider ownership percentage is immaterial for investors, but the filing signals continued participation in the company鈥檚 long-term incentive plan.

CEO & Director Karl G. Glassman filed a Form 4 showing the acquisition of 272.0722 Leggett & Platt (LEG) common shares on 07/25/2025 at an average price of $8.7805 (code A). Post-transaction, Glassman directly owns 1,427,943.7582 shares and indirectly holds 28,497.442 shares through the company鈥檚 retirement plan. No derivative activity or additional transactions were reported.

USANA Health Sciences (USNA) 鈥� Form 4 filing

On 24-Jul-2025, CEO & President Jim Brown converted 2,190 previously granted restricted stock units (code 鈥淢鈥�) into an equal number of common shares. To satisfy withholding taxes, 972 of those shares were automatically surrendered to the issuer at $32.09 per share (code 鈥淔鈥�). The net effect is an increase of 1,218 directly held shares, bringing Brown鈥檚 direct common-stock ownership to 16,934. He also retains 160,878 unvested/derivative RSUs that will convert into common shares as they vest. No open-market purchases or sales occurred; all transactions were internal equity-compensation settlements. The filing does not disclose any broader corporate developments.

USANA Health Sciences (USNA) Form 4 鈥� Director Ding Xia reported routine equity transactions dated 24 Jul 2025.

• Exercise of RSUs (Code M): 1,058 restricted stock units converted 1:1 into common shares, increasing direct holdings.
• Tax鈥恮ithholding sale (Code F): 265 shares were surrendered at $32.09 to satisfy withholding obligations.
• Post-transaction ownership: 5,337 common shares held directly and 3,172 unvested RSUs remain outstanding. RSUs vest 25 % on four quarterly dates between 24 Jul 2025 and 23 Apr 2026.

No purchase or sale of shares for investment purposes occurred; the net change (+793 shares) stems from normal equity compensation. No other directors or officers are listed, and there is no indication of material information affecting USNA鈥檚 operations or outlook.

USANA Health Sciences (USNA) Form 4: Director John Turman Fleming reported the automatic conversion of 1,058 Restricted Stock Units (RSUs) into an equal number of common shares on 24 Jul 2025 (transaction code M 鈥� derivative conversion). No cash price was paid at conversion.

Post-transaction holdings:

• Common stock held directly: 5,258 shares (up from 4,200).
• Unvested RSUs remaining: 3,172 units.

The RSU award vests in four equal tranches of 25% each on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. Fleming鈥檚 filing reflects the first vesting event. There was no open-market buying or selling; the transaction simply moves shares from derivative to common ownership, marginally increasing the director鈥檚 freely tradable stake.

Given the modest size relative to USNA鈥檚 ~19 million outstanding shares, the event is immaterial to corporate finances. It does, however, signal continued equity alignment between the director and shareholders.

USANA Health Sciences (USNA) 鈥� Form 4 filing: Director Gilbert A. Fuller reported the first vesting tranche of a previously granted restricted-stock-unit (RSU) award.

• Transaction date: 24 Jul 2025
• Type (Code M): automatic conversion of RSUs into common shares
• Shares acquired: 1,058 common shares at $0 cost
• Post-transaction ownership: 1,058 common shares held directly and 3,172 RSUs still outstanding
• Vesting schedule of remaining RSUs: 25 % on 23 Oct 2025, 22 Jan 2026, and 23 Apr 2026

The filing reflects routine equity-based compensation; no shares were sold and no cash proceeds were involved. The transaction is unlikely to materially affect the company鈥檚 share float or signal a directional view beyond normal incentive alignment.

USANA Health Sciences (USNA) 鈥� Form 4 insider filing: Director Peggie Pelosi reported RSU vesting and related share withholding on 24 Jul 2025. She converted 1,058 restricted stock units (code 鈥淢鈥�), adding the same number of common shares at a $0 exercise price. To cover taxes, 606 shares were withheld/sold (code 鈥淔鈥�) at $32.09, leaving a net increase of 452 shares.

Following the transactions, Pelosi now directly owns 4,135 common shares and still holds 3,172 un-vested/vested RSUs. No open-market purchases or discretionary sales were disclosed; the activity reflects scheduled equity compensation vesting. No changes to company guidance, operations, or financial metrics were included.